12 Month Price Forecast For AMGN
Distance to AMGN Price Forecasts
AMGN Price Momentum
🤔 Considering Amgen (AMGN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 11:07 PM UTC
AMGN Analyst Ratings & Price Targets
Based on our analysis of 39 Wall Street analysts, AMGN has a consensus that is neutral. The median price target is $331.50, with forecasts ranging from $195.00 to $405.00. Currently, there are 14 Buy ratings, 15 Hold ratings, and 3 Sell ratings.
With AMGN currently trading at $274.06, the median price forecast suggests a 21.0% upside. The most optimistic forecast comes from Olivia Brayer at Cantor Fitzgerald, projecting a 47.8% upside, while David Toung at Argus Research provides the most conservative target, suggesting a -28.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMGN Analyst Consensus
AMGN Price Target Range
Latest AMGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 10, 2024 | B of A Securities | Tim Anderson | Underperform | Reinstates | $256.00 |
| Nov 27, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $330.00 |
| Nov 15, 2024 | Wolfe Research | Tim Anderson | Peer Perform | Initiates | $0.00 |
| Nov 14, 2024 | Citigroup | Geoff Meacham | Neutral | Initiates | $335.00 |
| Nov 12, 2024 | Jefferies | Michael Yee | Buy | Maintains | $380.00 |
| Oct 31, 2024 | UBS | Colin Bristow | Neutral | Maintains | $326.00 |
| Oct 22, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $405.00 |
| Oct 21, 2024 | TD Cowen | Yaron Weber | Buy | Maintains | $383.00 |
| Oct 17, 2024 | Bernstein | Aaron Gal | Outperform | Initiates | $380.00 |
| Oct 14, 2024 | Truist Securities | Robyn Karnauskas | Hold | Downgrade | $333.00 |
| Oct 7, 2024 | Barclays | Carter Gould | Equal-Weight | Maintains | $315.00 |
| Sep 27, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Initiates | $405.00 |
| Sep 26, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $362.00 |
| Sep 25, 2024 | Baird | Brian Skorney | Underperform | Reiterates | $215.00 |
| Aug 7, 2024 | B of A Securities | Geoff Meacham | Neutral | Maintains | $330.00 |
| Aug 7, 2024 | Deutsche Bank | James Shin | Hold | Reiterates | $305.00 |
| Aug 7, 2024 | Wells Fargo | Mohit Bansal | Equal-Weight | Downgrade | $335.00 |
| Aug 7, 2024 | TD Cowen | Yaron Weber | Buy | Maintains | $381.00 |
| Aug 7, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $362.00 |
| Aug 7, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $380.00 |
Amgen Inc (AMGN) Financial Data
Amgen Inc has a market capitalization of $146.97B with a P/E ratio of 35.0x. The company generates $32.53B in trailing twelve-month revenue with a 13.0% profit margin.
Revenue growth is +23.2% quarter-over-quarter, while maintaining an operating margin of +24.2% and return on equity of +55.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Amgen Inc (AMGN) Company Overview
About Amgen Inc
Biopharmaceutical company developing human therapeutics.
The company discovers, develops, manufactures, and sells a range of human therapeutics primarily targeting chronic diseases and conditions. Amgen generates revenue by marketing its products to healthcare providers and directly to consumers, utilizing a distribution network that includes pharmaceutical wholesalers and clinics.
Amgen's extensive product portfolio includes treatments for autoimmune diseases, cancer, osteoporosis, and other serious conditions. The company actively engages in collaboration agreements with major pharmaceutical firms to enhance its product offerings and expand its market reach. Founded in 1980 and based in Thousand Oaks, California, Amgen is a leader in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
26,700
CEO
Mr. Robert A. Bradway
Country
United States
IPO Year
1984
Website
www.amgen.comAmgen Inc (AMGN) Latest News & Analysis
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
3 days agoAmgen's Board declared a $2.38 per share dividend for Q1 2025, reflecting the company's ongoing commitment to returning value to shareholders.
Amgen's dividend declaration signals financial stability and commitment to returning value to shareholders, potentially boosting investor confidence and stock demand.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
3 days agoAmgen (AMGN) has gained significant interest from Zacks.com users, indicating potential factors that could influence the stock's future performance.
Increased attention from users can signal heightened interest or potential volatility in Amgen's stock, influencing trading strategies and positioning by investors.
Here's Why Amgen (AMGN) is a Strong Value Stock
3 days agoZacks Style Scores help investors identify top-rated stocks tailored to their investing style, offering a straightforward tool for stock selection.
Zacks Style Scores help investors identify high-potential stocks aligned with their strategies, potentially enhancing portfolio performance and optimizing investment decisions.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
2 days agoAmgen (AMGN) closed at $273.41, down 0.85% from the previous trading day.
Amgen's slight decline to $273.41 signals potential volatility, impacting investor sentiment and decisions regarding the stock's near-term performance.
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
1 day agoZacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.
The Zacks Style Scores enhance stock selection across investment strategies, potentially improving returns and reducing risk, making it a valuable tool for informed investment decisions.
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
1 day agoThe stock market has had a strong year overall, but performance varies by sector, with some stocks underperforming compared to others.
Sector performance disparities indicate potential investment opportunities and risks, influencing portfolio strategies and stock selection for optimizing returns.
Frequently Asked Questions About AMGN Stock
What is Amgen Inc's (AMGN) stock forecast for 2025?
Based on our analysis of 39 Wall Street analysts, Amgen Inc (AMGN) has a median price target of $331.50. The highest price target is $405.00 and the lowest is $195.00.
Is AMGN stock a good investment in 2025?
According to current analyst ratings, AMGN has 14 Buy ratings, 15 Hold ratings, and 3 Sell ratings. The stock is currently trading at $274.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AMGN stock?
Wall Street analysts predict AMGN stock could reach $331.50 in the next 12 months. This represents a 21.0% increase from the current price of $274.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amgen Inc's business model?
The company discovers, develops, manufactures, and sells a range of human therapeutics primarily targeting chronic diseases and conditions. Amgen generates revenue by marketing its products to healthcare providers and directly to consumers, utilizing a distribution network that includes pharmaceutical wholesalers and clinics.
What is the highest forecasted price for AMGN Amgen Inc?
The highest price target for AMGN is $405.00 from Olivia Brayer at Cantor Fitzgerald, which represents a 47.8% increase from the current price of $274.06.
What is the lowest forecasted price for AMGN Amgen Inc?
The lowest price target for AMGN is $195.00 from David Toung at Argus Research, which represents a -28.8% decrease from the current price of $274.06.
What is the overall AMGN consensus from analysts for Amgen Inc?
The overall analyst consensus for AMGN is neutral. Out of 39 Wall Street analysts, 14 rate it as Buy, 15 as Hold, and 3 as Sell, with a median price target of $331.50.
How accurate are AMGN stock price projections?
Stock price projections, including those for Amgen Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
